Media.Player

Methods And Compositions For Treatment Of Endotoxin-Mediated Pro-Inflammatory Responses

Summary

Bacterial Lipopolysaccharide (Lps) In Systemic Circulation Triggers Deleterious Super-Inflammatory Response, Which Is Key Pathogenesis Of Many Disorders Like Gram-Negative Sepsis And Necrotizing Enterocolitis. No Effective Therapeutic Interventions Are Currently Available For Protection Of Patients Against Mortality. Disclosed Are Methods And Therapeutic Agents That Ablate The Biological Toxicity Of Lps In Circulation (Integrin Peptide), And Abrogate Leukocyte Infiltration Into Lung And Liver And Suppress Adhesion Molecule Expression (Integrin Peptide And Anti-Cd18 [Beta]A Scfv). These Therapeutic Agents Can Be Used Alone, Or In Combination For Treatment Of Endotoxin-Mediated Pro-Inflammatory Responses, Particularly In Cases Of Acute Sepsis And Necrotizing Enterocolitis.

Supplementary Information

Patent Number: US7960338B2
Application Number: US2009502548A
Inventor: Luk, John Moon Ching | Wong, Kwong Fai | Poon, Ronnie Tung Ping | Fan, Sheung Tat
Priority Date: 14 Jul 2008
Priority Number: US7960338B2
Application Date: 14 Jul 2009
Publication Date: 14 Jun 2011
IPC Current: A01N003718
US Class: 5140021 | 4242341 | 5140024 | 5140094 | 5140187 | 530350 | 530399
Assignee Applicant: The University of Hong Kong
Title: Methods and compositions for treatment of endotoxin-mediated pro-inflammatory responses
Usefulness: Methods and compositions for treatment of endotoxin-mediated pro-inflammatory responses
Summary: The antibody and integrin peptide are useful for treating a mammal (human) having an endotoxin-mediated inflammatory response and pro-inflammatory response (caused by the presence of bacterial lipopolysaccharide), which is acute sepsis (all claimed) and peritonitis. The effect of integrin peptide on the biological activity of endotoxin in circulation was determined by the LAL assay using the LAL pyrochrome kit in mice. The result showed that the integrin peptide exhibited a reduction of serum endotoxin level of 0.143± 0.03 Endotoxin Units (EU)/ml and 0.076± 0.001 EU/ml at 12 and 24 hours, respectively.
Novelty: New anti-CD 18 beta-A antibody comprising a single polypeptide chain having binding affinity to mammalian CD18 integrin in both resting and active conformations useful to treat acute sepsis and peritonitis

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

US2009502548A

Country/Region

Hong Kong